Hirofumi Amano

Nerima, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Anti-PM/Scl Antibody-Positive Dermatomyositis With Rapidly Progressive Interstitial Lung Disease in a 19-Year-Old Male: Clinical Implications of a Presumptive Diagnosis Based on Line Immunoassay Positivity.

Anti-PM/Scl Antibody-Positive Dermatomyositis With Rapidly Progressive Interstitial Lung Disease in a 19-Year-Old Male: Clinical Implications of a Presumptive Diagnosis Based on Line Immunoassay Positivity.

Journal: Cureus

Published: February 07, 2026

The guide for the diagnosis and treatment of connective tissue disease-associated interstitial lung disease 2025.

The guide for the diagnosis and treatment of connective tissue disease-associated interstitial lung disease 2025.

Journal: Respiratory investigation

Published: January 31, 2026

Efficacy of adding belimumab to hydroxychloroquine for patients with serologically active clinically quiescent in systemic lupus erythematosus: A retrospective study.

Efficacy of adding belimumab to hydroxychloroquine for patients with serologically active clinically quiescent in systemic lupus erythematosus: A retrospective study.

Journal: Lupus

Published: November 24, 2025

Bowenoid Actinic Keratosis in a Patient Receiving Abatacept for Rheumatoid Arthritis: A Case Report.

Bowenoid Actinic Keratosis in a Patient Receiving Abatacept for Rheumatoid Arthritis: A Case Report.

Journal: Cureus

Published: October 31, 2025

Developments in clinical practice treating systemic lupus erythematosus-A single-centre retrospective longitudinal study in Japan.

Developments in clinical practice treating systemic lupus erythematosus-A single-centre retrospective longitudinal study in Japan.

Journal: Modern rheumatology

Published: October 02, 2025

SLE-DAS remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in SLE remission and lupus low disease activity state.

SLE-DAS remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in SLE remission and lupus low disease activity state.

Journal: Rheumatology (Oxford, England)

Published: February 28, 2025

Analysis of the appropriate dose of hydroxychloroquine in systemic lupus erythematosus in Japan.

Analysis of the appropriate dose of hydroxychloroquine in systemic lupus erythematosus in Japan.

Journal: Modern rheumatology

Published: January 21, 2025

Other iatrogenic immunodeficiency-associated lymphoproliferative disorder presenting with multiple facial tumors.

Other iatrogenic immunodeficiency-associated lymphoproliferative disorder presenting with multiple facial tumors.

Journal: JAAD case reports

Published: June 14, 2024

Genetic dissection of HLA-DRB115:01 and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role for HLA-DRB115:01.

Genetic dissection of HLA-DRB115:01 and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role for HLA-DRB115:01.

Journal: RMD open

Published: April 08, 2023

Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

Clinical and Biomarker Responses to BI 655064, an Antagonistic Anti-CD40 Antibody, in Patients With Active Lupus Nephritis: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: March 17, 2023

Grafting of autologous concentrated bone marrow processed using a point-of-care device for patients with osteonecrosis of the femoral head: A phase 1 feasibility and safety study.

Grafting of autologous concentrated bone marrow processed using a point-of-care device for patients with osteonecrosis of the femoral head: A phase 1 feasibility and safety study.

Journal: Regenerative therapy

Published: November 28, 2021

Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial.

Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial.

Journal: Rheumatology (Oxford, England)

Published: November 25, 2021

Showing 1-12 of 31

Last Updated: 09/26/2026